235 related articles for article (PubMed ID: 28183048)
1. Potential impurities of anxiolytic drug, clobazam: Identification, synthesis and characterization using HPLC, LC-ESI/MS
Kumar N; Devineni SR; Dubey SK; Kumar P
J Pharm Biomed Anal; 2017 Apr; 137():268-278. PubMed ID: 28183048
[TBL] [Abstract][Full Text] [Related]
2. Four process-related potential new impurities in ticagrelor: Identification, isolation, characterization using HPLC, LC/ESI-MS(n), NMR and their synthesis.
Kumar N; Devineni SR; Gajjala PR; Gupta DK; Bhat S; Kumar R; Dubey SK; Kumar P
J Pharm Biomed Anal; 2016 Feb; 120():248-60. PubMed ID: 26760243
[TBL] [Abstract][Full Text] [Related]
3. Isolation, identification and characterization of two novel process-related impurities in olanzapine.
Zhuang T; Zhang W; Cao L; He K; Wang Y; Li J; Chen L; Liu B; Zhang G
J Pharm Biomed Anal; 2018 Apr; 152():188-196. PubMed ID: 29414012
[TBL] [Abstract][Full Text] [Related]
4. Isolation, identification and characterization of potential impurities of anidulafungin.
Zhao L; Wang Q; Bie Y; Lu X
J Pharm Biomed Anal; 2017 Jul; 141():192-199. PubMed ID: 28448888
[TBL] [Abstract][Full Text] [Related]
5. Highly efficient, selective, sensitive and stability indicating RP-HPLC-UV method for the quantitative determination of potential impurities and characterization of four novel impurities in eslicarbazepine acetate active pharmaceutical ingredient by LC/ESI-IT/MS/MS.
Thomas S; Bharti A; Maddhesia PK; Shandilya S; Agarwal A; Dharamvir ; Biswas S; Bhansal V; Gupta AK; Tewari PK; Mathela CS
J Pharm Biomed Anal; 2012 Mar; 61():165-75. PubMed ID: 22178334
[TBL] [Abstract][Full Text] [Related]
6. Forced degradation and impurity profiling: recent trends in analytical perspectives.
Jain D; Basniwal PK
J Pharm Biomed Anal; 2013 Dec; 86():11-35. PubMed ID: 23969330
[TBL] [Abstract][Full Text] [Related]
7. Isolation, identification, and characterization of potential impurities of doramectin and evaluation of their insecticidal activity.
Zhang Q; Cheng Y; Yang J; Zheng C; Lu X
J Pharm Biomed Anal; 2020 Nov; 191():113600. PubMed ID: 32977199
[TBL] [Abstract][Full Text] [Related]
8. Isolation, identification, characterization, synthesis and quality control strategy of new process-related impurities in ambrisentan.
Feng WD; Zhuo SM; Zhang FL
J Pharm Biomed Anal; 2019 Feb; 165():325-337. PubMed ID: 30579233
[TBL] [Abstract][Full Text] [Related]
9. Screening of synthetic PDE-5 inhibitors and their analogues as adulterants: analytical techniques and challenges.
Patel DN; Li L; Kee CL; Ge X; Low MY; Koh HL
J Pharm Biomed Anal; 2014 Jan; 87():176-90. PubMed ID: 23721687
[TBL] [Abstract][Full Text] [Related]
10. Identification, isolation, and synthesis of seven novel impurities of anti-diabetic drug Repaglinide.
Kancherla P; Keesari S; Alegete P; Khagga M; Das P
Drug Test Anal; 2018 Jan; 10(1):212-221. PubMed ID: 28421713
[TBL] [Abstract][Full Text] [Related]
11. Structural elucidation of impurities in 5-n-butyl-4-{4-[2-(1H-tetrazole-5-yl)-1H-pyrrol-1-yl]phenylmethyl}-2,4-dihydro-2-(2,6-dichlorophenyl)-3H-1,2,4-triazol-3-one (Ib), a novel nonpeptide angiotensin AT1 receptor antagonist.
Gao T; Liu Y; Ji Y; Wu X; Xu J
J Pharm Biomed Anal; 2012 Jul; 66():381-6. PubMed ID: 22516679
[TBL] [Abstract][Full Text] [Related]
12. Characterization of two unknown impurities in roxithromycin by 2D LC-QTOF/MS/MS and NMR.
Wang J; Zhou J; Xu Y; Zhu B; Jin Y
J Pharm Biomed Anal; 2020 May; 184():113196. PubMed ID: 32113121
[TBL] [Abstract][Full Text] [Related]
13. Critical practical aspects in the application of liquid chromatography-mass spectrometric studies for the characterization of impurities and degradation products.
Narayanam M; Handa T; Sharma P; Jhajra S; Muthe PK; Dappili PK; Shah RP; Singh S
J Pharm Biomed Anal; 2014 Jan; 87():191-217. PubMed ID: 23706957
[TBL] [Abstract][Full Text] [Related]
14. Isolation, identification and structure elucidation of two novel process-related impurities of retigabine.
Zhang D; Song X; Su J
J Pharm Biomed Anal; 2014 Oct; 99():22-7. PubMed ID: 25047423
[TBL] [Abstract][Full Text] [Related]
15. Structural elucidation of process-related impurities in escitalopram by LC/ESI-MS and NMR.
Raman B; Sharma BA; Ghugare PD; Nandavadekar S; Singh D; Karmuse PK; Kumar A
J Pharm Biomed Anal; 2010 Dec; 53(4):895-901. PubMed ID: 20655158
[TBL] [Abstract][Full Text] [Related]
16. Identification, isolation and characterization of potential process-related impurity and its degradation product in vildagliptin.
Kumar N; Devineni SR; Singh G; Kadirappa A; Dubey SK; Kumar P
J Pharm Biomed Anal; 2016 Feb; 119():114-21. PubMed ID: 26678178
[TBL] [Abstract][Full Text] [Related]
17. Impurity Profile of Bronchodilators used in Asthma: A Critical Review.
Prajapati KJ; Kothari CS
Curr Drug Discov Technol; 2018; 15(4):272-304. PubMed ID: 28875855
[TBL] [Abstract][Full Text] [Related]
18. Identification, characterization and quantification of new impurities by LC-ESI/MS/MS and LC-UV methods in rivastigmine tartrate active pharmaceutical ingredient.
Thomas S; Shandilya S; Bharati A; Paul SK; Agarwal A; Mathela CS
J Pharm Biomed Anal; 2012 Jan; 57():39-51. PubMed ID: 21880452
[TBL] [Abstract][Full Text] [Related]
19. Stability profiling of anti-malarial drug piperaquine phosphate and impurities by HPLC-UV, TOF-MS, ESI-MS and NMR.
Yan F; Liu J; Zeng X; Zhang Y; Hang T
Malar J; 2014 Oct; 13():401. PubMed ID: 25311421
[TBL] [Abstract][Full Text] [Related]
20. Isolation and characterization of process related impurities of olanzapine using HPLC and ESI-MS/MS.
Rao RN; Raju AN; Narsimha R; Babu GR
J Sep Sci; 2008 Jan; 31(1):107-18. PubMed ID: 18080239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
